CORDIS - EU research results
CORDIS

Commercial feasibility of an anti-bacterial treatment

Project description

Finding a solution for AMR

Antimicrobial resistance (AMR) is a major global threat to human and animal health. Medicines that were once effective treatments for disease are becoming less so, leading to a reduced ability to successfully treat infections. The EU-funded ABOLED project is investigating the commercial viability of an alternative approach to this problem. AMR is responsible for an estimated 33 000 deaths per year in the EU. It is also estimated that AMR costs the EU EUR 1.5 billion per year in healthcare costs and productivity losses. Only 25 % of countries have implemented a national policy to tackle AMR. Less than 40 % of countries have put in place infection prevention and control programmes for AMR.

Objective

Multidrug resistance of pathogenic bacteria has become a serious threat to public health. The need to develop novel technologies to combat the evolution of bacterial drug resistance is clearly a matter of public concern and urgency. The consequences of AMR include (i) reducing our ability to treat common infectious, resulting in prolonged illness and a greater risk of complications; (ii) patients remaining infectious for longer due to ineffective treatments, making them more likely to pass infections on to others; (iii) compromising advances in modern medicine (such as organ transplantation or chemotherapy) due to risk of infection; and (iv) increasing economic burden on health care systems, families, and societies. This project aims to assess the commercial viability of an alternative approach to this problem.

Host institution

THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
Net EU contribution
€ 150 000,00
Address
NORTH STREET 66 COLLEGE GATE
KY16 9AJ St Andrews
United Kingdom

See on map

Region
Scotland Eastern Scotland Clackmannanshire and Fife
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)